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Abstract
Objective
The aim of the present study was to assess the degree and impact of patient selection of
patients with intermittent claudication undergoing supervised exercise therapy in Random-
ized Controlled Trials (RCTs) by describing commonly used exclusion criteria, and by com-
paring baseline characteristics and treatment response measured as improvement in
maximum walking distance of patients included in RCTs and patients treated in standard
care.
Methods
We compared data from RCTs with unselected standard care data. First, we systematically
reviewed RCTs that investigated the effect of supervised exercise therapy in patients with
intermittent claudication. For each of the RCTs, we extracted and categorized the eligibility
criteria and their justifications. To assess whether people in RCTs (n = 1,440) differed from
patients treated in daily practice (n = 3,513), in terms of demographics, comorbidity and
walking capacity, we assessed between group-differences using t-tests. To assess differ-
ences in treatment response, we compared walking distances at three and six months
between groups using t-tests. Differences of15% were set as a marker for a clinically rele-
vant difference.
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Results
All 20 included RCTs excluded large segments of patients with intermittent claudication.
One-third of the RCTs eligibility criteria were justified. Despite, the numerous eligibility crite-
ria, we found that baseline characteristics were largely comparable. A statistically significant
and (borderline) clinically relevant difference in treatment response after three and six
months between trial participants and standard care patients was found. Improvements in
maximum walking distance after three and six months were significantly and clinically less
in trial participants.
Conclusions
The finding that baseline characteristics of patients included in RCTs and patients treated in
standard care were comparable, may indicate that RCT eligibility criteria are used implicitly
by professionals when referring patients to standard physiotherapy care. The larger treat-
ment response reported in standard physiotherapy care compared to clinical trials, might
suggest that scientific studies underestimate the benefits of supervised exercise therapy in
patients with intermittent claudication.
Introduction
“Can I translate results found in patients enrolled in a randomized controlled trial (RCT) to the
patient I am treating in my daily clinical practice?” This is one of the fundamental questions
healthcare professionals have to ask themselves when interpreting scientific evidence. Con-
cerns frequently arise as to how well a therapy may perform beyond highly selected patient
populations and in different clinical settings than those studied in RCTs [1–5].
Differences between patients participating in RCTs and patients treated in standard care, as
well as differences in clinical interventions between RCTs and standard care might affect the effec-
tiveness of a therapy. Randomized controlled trials are only able to guide standard care and clini-
cal decision-making when the research findings can be expected to be similar in other groups of
patients not included [6, 7]. This requirement is not always met, which makes it difficult for clini-
cians to know to what extent the evidence for the effectiveness of an intervention applies to a
given patient [8]. In this study, we aim to illustrate the degree of patient selection in RCTs by com-
paring baseline characteristics of patients included in clinical trials and patients treated in stan-
dard physiotherapy care. Furthermore, we aim to describe the differences in treatment response
between patients enrolled in RCTs and those treated in standard care. Patients with intermittent
claudication undergoing supervised exercise therapy are used as a case example, as our group has
ample experience with both intermittent claudication and supervised exercise therapy (helping us
to correctly interpret the utilized eligibility criteria) and access to a large, well-documented, unse-
lected database of patients with intermittent claudication undergoing supervised exercise therapy
(allowing a direct comparison between scientific research and real-life practice).
We aim to address the following three research questions:
1. Which patients with intermittent claudication are excluded in RCTs studying the effect of
supervised exercise therapy and what are the reasons for excluding these patients?
2. To what extent are baseline characteristics of patients with intermittent claudication
included in RCTs and patients with intermittent claudication treated with supervised exer-
cise therapy in standard care comparable?
Extent and Impact of Patient Selection
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3. To what extent are supervised exercise therapy treatment responses (in terms of maximum
walking distance) after three and six months of patients included in RCTs and patients
treated in standard physiotherapy care comparable?
We hypothesized that, due to a strict selection of patients with intermittent claudication
participating in RCTs (favouring less complex patients), the baseline maximum walking dis-
tance and the improvement in maximum walking distance after three and six months of super-
vised exercise therapy is larger in RCTs as compared to the treatment responses of patients
with intermittent claudication treated in standard supervised exercise therapy care.
Materials and Methods
Study design
We used the convergent parallel design [9] to compare two separate data sources: 1. data from
RCTs investigating the effect of supervised exercise therapy in patients with intermittent clau-
dication and 2. data from patients with intermittent claudication treated with supervised exer-
cise therapy in the context of standard care physiotherapy. Both data sources were extracted
and analyzed during the same phase of this study. Using qualitative data on the applied eligibil-
ity criteria and their justifications, we studied the extent of patient selection in RCTs. We
extracted quantitative data of baseline characteristics and maximum walking distance from
RCTs, and compared it with data from standard care physiotherapy to study differences at
baseline and in treatment response after three and six months between patients included in
RCTs and patients treated in standard care. Both qualitative and quantitative data were com-
bined to formulate an overall interpretation of the results. To enhance transparency and repro-
ducibility this article is written according to the Preferred Reporting Items for Systematic
reviews and Meta-Analysis (PRISMA) presented in S1 PRISMA Checklist [10].
Systematic review
Information sources and search. We performed a systematic search of articles from sci-
entific medical journals published in the electronic online databases MEDLINE (PubMed),
Embase (Ovid) and Cochrane Library up to mid-August 2015. The search strategy was devel-
oped by SD and TH and included MeSH terms and keywords and is presented in S1 Table. To
identify additional articles, all reference lists were checked for further relevant citations. We
compared trials reporting information on the same set of patients and only included those with
the most complete information on the patients’ baseline characteristics and treatment
response.
Study selection. Studies were eligible for inclusion if: 1. the design was an RCT comparing
supervised exercise therapy in patients with symptomatic peripheral arterial disease with stan-
dard care and/or other exercise recommendations. We focus on RCTs only, because they are
accepted as the most unbiased measure of the efficacy of an intervention. Only RCTs compar-
ing supervised exercise therapy with standard care and/or any other exercise recommendation
and not RCTs comparing supervised exercise therapy with supervised exercise therapy with
some kind of augmentation to it are included, because these effectiveness trials (using two
treatments that lie within the range of usual-care practices) are the RCTs that are typically used
to communicate the effectiveness of supervised exercise therapy to stakeholders. Due to the
fact that we inquire to evaluate the effectiveness of supervised exercise therapy only effective-
ness trials are included; 2. Peripheral arterial disease was diagnosed by the Ankle-Brachial
Index (ABI)<0.9 in rest and/or<0.73 after exercise, because these are the criteria for patients
to enter physiotherapy care; 3. the duration of supervised exercise therapy was at least three
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months, so as to be able to compare supervised exercise therapy treatment response between
RCTs and standard care [11]; 4. the authors reported maximum walking distance or time mea-
sured by a graded treadmill test so that the outcome measure between RCT and standard care
is equivalent or can be recalculated to become equivalent. All citations were independently
screened and reviewed by SD and TH using the online software for intervention reviews Covi-
dence supported by Cochrane [12]. We identified RCTs investigating the effect of supervised
exercise therapy in patients with intermittent claudication on the basis of title and abstract. A
more detailed inquiry based on full-text screening ensured that only articles fulfilling the eligi-
bility criteria mentioned above were included in the meta-analysis.
Data collection process and data items. To evaluate eligibility criteria used and reasons
for excluding specific patients, we listed first author, publication year and eligibility criteria per
trial. In a second table, we recorded justifications for eligibility criteria applied per RCT. Infor-
mation on eligibility criteria and justifications for eligibility criteria used was extracted in dupli-
cate by SD and TH.
To extract relevant data on baseline characteristics we used a self-designed, standardized
data extraction form. Data about the author, the publication year, the country in which the
RCT was conducted, the mean age (years), the percentage of males, the mean body mass index
(kg/m2), the percentage of smokers and mean baseline maximum walking distance in meters of
the supervised exercise therapy group was listed by TH and checked by SD. Only data from the
supervised exercise therapy group of RCTs was used, because the aim of the present study is to
compare research data with patients treated with supervised exercise therapy in standard care
physiotherapy.
We extracted data on treatment outcome using a second self-designed standardized data
sheet. Data extraction was done by SD and controlled by TH. We obtained exercise training
and testing parameters (exercise type, exercise length, exercise duration, exercise frequency,
walking speed, presence/absence of supervision and treadmill test protocol). In addition, we
listed the number of patients that received supervised exercise therapy as well as mean maxi-
mum walking distance in meters after three and six months. Maximum walking distance pre-
sented in time (minutes or miles per hour) as well as maximum walking distance recorded in
feet was converted into meters [13, 14].
Risk of bias across studies. We assumed that summary statistics on treatment outcome,
defined as maximum walking distance, were adequately reported in all 20 RCTs. A normal dis-
tribution of data was assumed to be present in trials reporting mean maximum walking dis-
tance and standard deviation (SD) and a skewed data distribution was supposed to be present
in trials reporting median and Interquartile range (IQR). Because in a skewed distribution the
mean is pulled in the direction of extreme scores (tail), inadequate use of the summary statistic
mean in RCTs included may have introduced over-reporting of maximum walking distance in
case of right skewed data and under-reporting of maximum walking distance in case of left
skewed data.
Quality assessment. The Physiotherapy Evidence Database PEDro stores RCTs conducted
in the field of physiotherapy research. This database is updated once a month. The methodo-
logical quality of all RCTs stored in the database is rated with the PEDro scale by the well-
trained staff of the Centre for Evidence-Based Physiotherapy. Results of the assessment of the
methodological quality of trials are also published in the PEDro database. To ensure the quality
of ratings all raters underwent training; all RCTs are rated twice; a third rater resolved possible
disagreements; informal and non-systematic checks of the quality of some ratings were per-
formed; and the opportunity for PEDro users to dispute trial ratings is offered.
The PEDro scale is a checklist of 11 scored questions (yes or no) rating the methodological
quality of RCTs. Criteria focus on the external validity (criterion 1), the internal validity
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(criterion 2–9) and the statistical information provided (criterion 10 and 11). A ‘yes’ is only
awarded when a criterion is clearly satisfied. Each satisfied item contributes one point to the
total PEDro score (0 to 10 points), except for item 1 which is the only item related to the exter-
nal validity of the trial. The PEDro scale is based on a Delphi list developed by Verhagen et al.
[15] Results of previous research show that the PEDro scale is reliable for use in systematic
reviews of physiotherapy RCTs [16]. We found information about the methodological quality
of all RCTs included in the present study in PEDro, except for Mays et al. [17], a very recent
RCT. The methodological quality of this RCT was rated in duplicate (by SD and TH) using the
PEDro scale. No disagreements between both raters occurred.
Standard physiotherapy care data
We used data from patients with a physician-confirmed symptomatic peripheral arterial dis-
ease (ABI<0.9 at rest) who were treated with supervised exercise therapy in standard care
physiotherapy between 2006 and 2011. Patient data were prospectively collected by 197 physio-
therapists using Electronic Medical Records. We did not include data of patients without a
baseline measurement in the present study, because one aim was to compare baseline charac-
teristics of patients enrolled in trials with baseline characteristics of patients treated in standard
care physiotherapy.
Data of patient characteristics recorded in the electronic medical record include information
on age, gender, BMI, smoking behavior and comorbidity. The BMI of each patient was calcu-
lated according to the clinical guideline on the Identification, Evaluation and Treatment of
Overweight and Obesity in adults [18]. Smoking behavior was recorded as current smoker or
current non-smoker. The presence or absence of cardiovascular comorbidity, pulmonary
comorbidity, internal comorbidity, orthopedic comorbidity and neurologic comorbidity was
recorded according to the standard hospital registration. Diseases belonging to all categories of
comorbidity are listed in S2 Table. Patients were treated with supervised exercise therapy
according to the evidence-based guideline intermittent claudication recommendation of the
Royal Dutch Society for Physical Therapy [19]. The primary outcome measurement of the
therapy was improvement in maximum walking distance. To measure maximum walking dis-
tance, physiotherapists performed a standardized graded treadmill test according to the tread-
mill test protocol described by Gardner et al [20]. All data was gathered in the context of
standard care physiotherapy. The ethics committee/institutional review board 'Medisch
Ethische Toetsingscommissie van AtriumMedisch Centrum, Orbis Medisch en Zorgconcern
en Zuyd Hogeschool' approved at August, 19th 2013 the physiotherapy cohort study. Data was
gathered in the context of standard care. All participants signed written informed consent for
their clinical records to be used and patient records/information was anonymized and de-iden-
tified prior to analysis (METC number: 13-N-85).
Data analysis
Because inclusion and exclusion criteria are interchangeable by merely adding a ‘not’ to any
given criterion, we studied both to receive a complete picture of the eligibility criteria applied.
To evaluate which eligibility criteria were applied in the included RCTs, SD and TH first inde-
pendently listed all eligibility criteria per RCT. Subsequently, both researchers in consultation
categorized each of the inclusion and exclusion criteria. The following categories were created:
‘patient characteristics’, ‘unstable medication use’, ‘comorbidity’, ‘walking capacity’ and ‘other
criteria’. Both assessors independently counted the number of trials in which the criteria per
category occurred; counts and percentages were listed. Finally, both researchers checked
whether and how often justifications for applied eligibility criteria were provided. With regard
Extent and Impact of Patient Selection
PLOS ONE | DOI:10.1371/journal.pone.0157921 June 23, 2016 5 / 19
to comorbidity, the percentage of RCT participants with comorbidity was noted per RCT.
Comorbidity reported in RCTs was often disease-specific. To be able to compare RCT partici-
pants with standard care physiotherapy patients with regard to comorbidity, we categorized
disease-specific comorbidities listed in the RCTs into the categories of comorbidity that were
used in the standard physiotherapy care EMR data, namely: cardiovascular, pulmonary, inter-
nal, orthopedic and neurologic comorbidity. The disease-specific comorbidity reporting in
RCTs did not allow us to estimate the percentage of participants with comorbidity per category
due to possible double-counts of participants. Therefore, we calculated a worst-case and a best
case-scenario. In the worst-case scenario, disease-specific cases of comorbidity were added up
per RCT and per category. In the best-case scenario, the highest percentage comorbidity per
category and RCT was listed. We compared both scenarios with the percentage of comorbidity
in standard care patients. For the sake of clear presentation in the text, the average percentage
between worst-case and best-case scenario will be presented.
To compare baseline characteristics of patients included in RCTs and patients seen in stan-
dard physiotherapy care, we first pooled relevant baseline characteristics (age, sex, BMI,
smoker (yes/no), and maximum walking distance) of all individual trials according to the
methods described in the Cochrane Handbook [21]. Second, we tested whether the pooled esti-
mates from the RCTs were significantly different from the estimates of the same baseline char-
acteristics of the standard care physiotherapy cohort, using t-tests. In addition, we depicted
mean maximum walking distance and their respective SDs per study and for the cohort in a
forest plot to allow visual comparison. To investigate whether treatment response after super-
vised exercise therapy differs between treatment in standard care and treatment in RCTs, we
described the differences in maximum walking distance in meters after three and six months.
Median maximum walking distance after three and six months of standard care was compared
with pooled estimates of the treatment response measured in RCTs using a t-test. Furthermore,
a difference in maximum walking distance between patients included in RCTs and patients
treated in standard care of15% was set as a marker for a clinically relevant difference [22].
We performed sensitivity analysis to take care of different treadmill protocols used to assess
maximum walking distance in different RCTs.
Results
Overall, RCTs provided data about 1,440 patients, and we used data of 3,531 patients from
standard care physiotherapy. First, we present the results of our systematic review on RCTs
investigating the effect of supervised exercise therapy in patients with intermittent claudication.
Then, we show information about the eligibility criteria applied in RCTs and reasons for exclu-
sion, followed by the results of our comparison of RCT data and standard care data at baseline
and after three and six months.
Study selection
The systematic search identified 16,551 potentially eligible articles in total, and 72 full-text
RCTs were recognized for possible inclusion. During full-text screening, we excluded RCTs for
the following reasons: a comparator other than any exercise recommendation or ‘doing noth-
ing’ (12%); inappropriate patient group(s) (14%); maximum walking distance or walking time
was not reported (14%); a nonrandomized design (6%); or supervised exercise therapy was not
the intervention (35%). After identification of duplicate reports (21%), 20 eligible RCTs
remained. A flow diagram of screened, eligible and included randomized controlled trials is
presented in Fig 1 [17, 23–41].
Extent and Impact of Patient Selection
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Methodological quality
Total PEDro quality scores varied from 3 to 7 out of a maximum of 10 points. In all RCTs bias
occurred due to a lack of blinding of subjects and therapists. In addition, 80% of the trials
reported that group allocation was not concealed, 75% had no blinded assessors and 55% of all
RCTs did not report information about an intention-to-treat analysis (S3 Table).
Inventory of eligibility criteria and reasons for exclusion
Patient characteristics were the reason for exclusion in 30% of the RCTs (Table 1). Patients
younger than 18 were excluded most often (20% of trials). (Unstable) lipid lowering, anti-plate-
let and antihypertensive medication use was the reason for exclusion in 65% of the trials.
Patients were excluded due to the presence of comorbidity in all trials. Cardiovascular comor-
bidity (85%) and internal comorbidity (50%) were the main comorbidities for exclusion.
Fig 1. Flow diagram of screened, eligible and included randomized controlled trials.
doi:10.1371/journal.pone.0157921.g001
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Patients that suffer from a pulmonary and/or an orthopedic comorbidity were excluded in 40%
of the trials. Impairment in walking capacity was the reason for exclusion in 70% of the RCTs.
Being unable to walk on a treadmill with at least a speed of 3.2 km/h (35%) and gait abnormali-
ties that had a different cause than peripheral arterial disease (45%) were most often reported.
Other criteria were the reason for exclusion in 55% of the trials. Within this group, vascular
surgery, angioplasty, lumbar sympathectomy and lower extremity revascularization in the six
Table 1. Summary of eligibility criteria used in all RCTs.
Eligibility criteria No (%) of RCTs in which each eligibility criterion
was applied
Patient characteristics 6 (30)
Age
<18 year 4 (20)
>70 year 1 (5)
Sex Female 1 (5)
Women in menopausal status and those taking
estrogen
1 (5)
BMI  30 kg/m2 1 (5)
Unstable medication use 13 (65)
Comorbidity 20 (100)
Cardiovascular 17 (85)
Pulmonary 8 (40)
Internal 10 (50)
Orthopedic 8 (40)
Neurologic 5 (25)
Walking capacity 14 (70)
Unable to walk on a treadmill at a speed of at least
3.2 km/h
7 (35)
Gait abnormalities not due to peripheral arterial
disease
9 (45)
Maximum walking distance >1600 meter at
baseline
1 (5)
Maximum walking distance  500 meter at baseline 1 (5)
Maximum pain-free walking distance <150 meter 1 (5)
No functional limitation due to IC during treadmill
test
3 (15)
Other criteria 11 (55)
Concurrent supervised exercise therapy 4 (20)
No native speaker 2 (10)
No insurance for supervised exercise therapy 1 (5)
Invasive peripheral arterial disease treatment
(preceding 6 months or planned)
14 (70)
Substance abuse 1 (5)
Not living independently 2 (10)
Inability and/or unwillingness to exercise 4 (20)
Inability to obtain ABI 3 (15)
Rest leg pain 4 (20)
Unstable intermittent claudication symptoms
(preceding 3 months)
1 (5)
Abbreviations: BMI = body mass index
doi:10.1371/journal.pone.0157921.t001
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months preceding or scheduled at the start of the trial were the main reason for exclusion
(70%) (Table 1).
Regarding the presence of comorbidity, we found that cardiovascular comorbidity (65% vs
43%) and neurologic comorbidity (24% vs 12%) were more prevalent in standard care than in
RCTs, respectively. Pulmonary (18% vs 16%), orthopedic (24% vs 20%) and internal comorbid-
ity (54% vs 58%) were comparable between standard care and RCTs, respectively (S4 Table).
Eligibility criteria were justified by authors in 30% of the RCTs [26, 29, 30, 33, 36, 37]. For
instance, Gardner et al. [26] referred to the Guidelines of the American college of Sports Medi-
cine [42] and a study conducted by Regensteiner et al. [43] for justification. The other five
RCTs [26, 29, 33, 36, 37] reported detailed rationales for the applied eligibility criteria. Most
frequent reasons for applied exclusion criteria were: (1) that the response to supervised exercise
therapy might be affected by a certain characteristic; (2) that the aim of the study requires
exclusion of certain groups of participants; (3) that patients with certain characteristics were
not likely to complete supervised exercise therapy; (4) that the characteristic might limit and/
or alter walking ability (see S5 Table for details).
Description and comparison of RCT data and standard care data at
baseline
A description of RCT data and standard care data is displayed in Table 2. Supervised treadmill
walking, coached by a physiotherapist or another exercise specialist was the type of exercise in
nearly all RCTs and in standard physiotherapy care. In trials supervised exercise therapy was
performed on average for 22 weeks, three times a week with on average 42 minutes per exercise
session. In standard physiotherapy care supervised exercise therapy was performed for on aver-
age 26 weeks, two to three times a week for 30 minutes per exercise session.
The mean (SD) age of patients with IC included in the RCTs and patients with IC that were
referred to the physiotherapist for the treatment of supervised exercise therapy was 67 years in
both groups. The percentage of males was significantly higher in the trial patients (73%) com-
pared to the standard physiotherapy care patients (62%). The body mass index of patients
treated in standard care was significantly higher in patients included in RCTs (26.7 kg/m2 vs
26.0 kg/m2, p< 0.05).
Mean baseline maximum walking distance was 382 m (range 116 to 805 m) in the 20 RCTs.
No difference in baseline maximum walking distance between RCTs with a three months and/
or six- months follow up period was found (375m, SD: 218m versus 370m, SD: 216m). In the
standard supervised exercise therapy care population mean baseline maximum walking dis-
tance was 10 m less; this difference was not clinically relevant (3.14%) nor statistically signifi-
cant (p = 0.232). Thirteen of the 20 RCTs reported higher mean maximum walking distance at
baseline than in standard supervised exercise therapy care (Fig 2).
Comparison of treatment response
Maximum walking distance after three months was studied in 65% and after six months in
35% of all RCTs. After three months maximum walking distance in RCTs was on average 605
m (range: 178 to 1100 m) and after six months 641 m (range: 610 to 956 m). After three and six
months, improvement in maximum walking distance was greater in patients treated with
supervised exercise therapy in standard physiotherapy care compared to patients included in
RCTs (58 mmore improvement after 3 months and 159 mmore improvement after 6 months).
After three and six months of supervised exercise therapy, the difference in improvement in
maximum walking distance between patients included in RCT and patients from standard care
was statistically significant (both p< 0.01). A clinically relevant difference (15%) between
Extent and Impact of Patient Selection
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patients included in RCTs and patients treated in standard care was only found after six
months of supervised exercise therapy (maximum walking distance improvement in patients
treated in standard care was 24.80% higher). After three months of supervised exercise therapy
the improvement in maximum walking distance was 14% higher in patients treated in standard
physiotherapy care compared to patients included in RCTs and thus borderline clinically rele-
vant (Table 2).
Sensitivity analysis
In some RCTs researchers used different treadmill protocols to assess maximum walking dis-
tance [44, 45] we found, however, that this did not result in differences in maximum walking
distance assessed at baseline.
Discussion
All RCTs included in the present study excluded moderate to large segments of the population
of patients with intermittent claudication, and the exclusion criteria applied were justified in
only a third of the trials. It seems that most of the exclusion criteria are also implicitly used in
standard physiotherapy care, because baseline characteristics of patients included in RCTs and
Fig 2. Forest plot illustrating the mean (SD) baseline maximumwalking distance of patients included in the 20
RCTs and patients treated in standard supervised exercise therapy care.
doi:10.1371/journal.pone.0157921.g002
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patients treated in standard physiotherapy care were comparable. However, a statistically sig-
nificant and (borderline) clinically relevant difference in the improvement in maximum walk-
ing distance after three and six months was found. The difference between trial treatment
response and standard physiotherapy care treatment response suggests an underestimation of
the benefits of supervised exercise therapy for the standard physiotherapy care setting.
The strengths of our study include the rigorous literature search, the data extraction check
and the availability of a large real-life standard care supervised exercise therapy data registry.
There are also some limitations. First, we did not have data on the exclusion criteria used in
standard physiotherapy care, making a head-on comparison impossible. Second, due to a lack
of disease-specific reporting of comorbidity in the standard care data, we could not compare
patients included in trials exactly with patients treated in standard supervised exercise therapy
care with regard to disease-specific comorbidity. Third, no information on possible supervised
exercise therapy adaptations applied in standard physiotherapy care was available, nor did any
of the RCTs provide treatment fidelity estimates. Finally, we had no control over how well stan-
dard supervised exercise therapy care data was recorded. Nevertheless, data on 3,531 patients
was collected by 197 different physiotherapists and therefore we are inclined to accept that
quality differences will balance out due to the large number of physiotherapists registering the
data.
Our inventory of eligibility criteria and justifications for eligibility criteria used in RCTs
investigating the effect of supervised exercise therapy in patients with intermittent claudication
showed that all trials excluded large segments of the population of patients with intermittent
claudication, yet this did not result in major differences at baseline. Patients were excluded due
to comorbidity in all 20 RCTs. Cardiovascular comorbidity was the reason for exclusion in
85% of the RCTs and only one article justified this exclusion criteria, stating that cardiac symp-
toms might limit walking ability of patients with intermittent claudication to a greater extent
than peripheral arterial disease [33]. Coronary artery disease was shown to be present in 46%
to 58% of all patients with intermittent claudication [46, 47], which implies that the exclusion
of patients with this comorbidity leaves half of patients with intermittent claudication with
uncertainty and potential unintended harm from generalizing trial results. Due to the fact that
RCTs have limited financial resources, follow a strict intervention protocol and cardiac exercise
testing would be recommended before the start of supervised exercise therapy, [11] the exclu-
sion of patients with cardiovascular comorbidity seems understandable; however, this has the
consequence of limiting the generalizability of the RCTs results. Patients who received invasive
treatment in the preceding six months or were scheduled for an invasive intervention were also
often excluded. McDermott et al. [33] excluded this patient group because lower extremity
revascularization may alter walking ability. This justification is in line with previous research
that has shown that invasive treatment is effective in increasing maximum walking distance at
a follow-up to 12 months [48, 49]. Medication use (unstable and in general) as well as impair-
ments in walking capacity were also reported as exclusion criteria in the majority of included
RCTs, again with limited justification. A rationale for the eligibility criteria used is hardly ever
provided, although international ethical guidelines for research involving human subjects [50,
51] and the CONSORT and the SPIRIT statement require justification of exclusion of study
populations [52, 53]. Gardner et al. [26] did not explicitly report rationales for exclusion, but
provided references [42, 43] as support for the exclusion criteria applied. However, these refer-
ences are complex documents that keep the reader guessing about the exact reasons why
patients have been deliberately excluded. The justification for exclusion criteria applied was
made transparent on a more general level; hence explicit reporting is necessary to study con-
cerns of unjustifiable exclusion of the study population. None of the 20 RCTs reported how
many patients were excluded per eligibility criterion. Regardless, we also found that the
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majority of baseline characteristics of patients with intermittent claudication included in RCTs
and patients with intermittent claudication treated in standard care were comparable (age,
BMI, smoking behavior, comorbidity and maximum walking distance). We did observe a
higher number of male patients in the RCTs, but we are unable to formulate a logical rationale
for this difference. Our a-priori hypothesis that baseline maximum walking distance would be
lower in standard supervised exercise therapy practice was thus rejected. This leads us to assume
that patients with certain types of comorbidity are also not part of standard practice. There might
be multiple underlying reasons. It could be that the impact of comorbidity on walking ability,
exercise capacity, its severity or in general the presence of comorbidity discourages patients from
seeking physiotherapy treatment. Previous research showed that comorbidity may require adap-
tations in physiotherapy as comorbidity negatively affects treatment outcomes of the index dis-
ease or as treatment for one disease may negatively interact with the treatment or natural course
of the comorbidity [54]. It might also be that physiotherapists recognize additional risks of exer-
cise training that emerge due to comorbidity and therefore advise against supervised exercise
therapy [11]. Whatever the reason, we conclude that the degree of selection bias in RCTs on
supervised exercise therapy in people with intermittent claudication is minimal and would there-
fore likely reflect the general population of individuals with intermittent claudication.
Improvement in maximum walking distance after three and six months of supervised exer-
cise therapy was significantly greater–both statistically as well as clinically–for patients treated
in standard physiotherapy care compared to patients treated in RCTs, refuting our a-priori
hypothesis. Considering that baseline maximum walking distance values were comparable, this
difference might be attributed to differences in the utilized supervised exercise therapy treat-
ment protocols. In general, patients in the RCTs and in standard care received supervised exer-
cise therapy on a treadmill, three times a week at a walking speed of 3.2 km/h, except for the
trial of McDermott et al. [35] where patients walked around an indoor track. Despite the fact
that exercise duration per treatment session was on average 12 minutes longer in RCTs than in
standard care, no striking differences between the description of supervised exercise therapy as
applied in the RCTs and in standard care were found that explain this substantial disparity in
treatment response; both largely follow the current recommendations for optimal supervised
exercise therapy [55–57]. In our opinion, there are two possible explanations for the differences
in treatment response: the therapeutic quality and fidelity of the provided interventions and
differences in utilized methods. First, we expect that the therapeutic quality of the supervised
exercise therapy interventions in standard practice is greater in comparison to supervised exer-
cise therapy in RCTs. After all, specialized and well-trained therapists have considerable expe-
rience providing supervised exercise therapy to people with intermittent claudication, likely
resulting in more personalized therapeutic interventions, as compared to the often rigid and
highly standardized interventions provided in RCTs [58]. Following a highly standardized
supervised exercise therapy protocol might cause the ‘better patients’ to be insufficiently chal-
lenged, while in standard care supervised exercise therapy treatment protocols might have
been tailored to the individual patient circumstances in order to gain the maximum improve-
ment in maximum walking distance. A fully detailed description of the intervention applied in
RCTs is recommended by the Consolidated Standards of Reporting Trials (CONSORT) [51].
All RCTs included in the present study present a moderate level of detail about supervised
exercise therapy. Although, it might not be possible to present a great level of detail in scientific
articles, we support the suggestion by Schulz et al. [59] to post links to websides that then pro-
vide a detailed description of the intervention applied in the RCT.
Moreover, trial participants may have been limited in their choice of possible co-interven-
tions; after all, co-intervention is typically seen as a potential source of bias in RCTs. In con-
trast, patients with intermittent claudication who are referred to standard physiotherapy care
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for supervised exercise therapy will likely receive additional therapeutic recommendations,
home-exercise programs and perhaps even treatment, which in turn could lead to a greater
improvement in maximum walking distance over time.
Moreover, it is important to highlight that data from standard physiotherapy care was col-
lected between 2006 and 2011 and SET was back then in its infancy [60, 61]. Based on the posi-
tive effect of SET, in 2011 a nationwide community based SET network (ClaudicatioNet) was
initiated and launched in the Netherlands. The forefront of ClaudicatioNet is formed by spe-
cialised physical therapists providing high quality SET, stimulating lifestyle changes and medi-
cation adherence [62, 63]. Due to the progress in quality of SET care we speculate that
repeating the present study with more recent standard care data might result in even a larger
discrepancy between SET effectiveness presented in RCTs and SET applied in standard care.
Our assessment of the methodological quality of RCTs included showed that in all RCTs bias
occurred because of lack of blinding and intention-to-treat analysis. Blinding is a critical method-
ological part of RCTs. However, the results of our quality assessment indicated that 100% of the
included RCTs did not blind subjects and therapists and that the assessor was blinded in only a
quarter of the studies. A number of studies previously reported a significant difference in the size
of the estimated treatment effect between trials that reported blinding compared to those that did
not (p = 0.01), with an overall odds ratio 17% larger in studies that did not report ‘double-blind-
ing’ [64–66]. Because none of the 20 included RCTs reported ‘double-blinding’, their estimated
treatment effect represents an underestimation (-17%) of treatment effectiveness in ideal meth-
odological circumstances. This means that our RCT data is more comparable to the standard
care data (no blinding), and that even despite the fact that the estimate of treatment effectiveness
in RCTs is underestimated by 17% a statistical and (borderline) clinically relevant difference in
treatment effectiveness has been detected after three and six months. Moreover, blinding of the
outcome assessor is crucial to ensure unbiased ascertainment of treatment effectiveness [67].
However, the lack of blinding techniques that has been detected in the majority of RCTs included
in the present study also enhances the comparability with our standard care data.
Less than half of all included RCTs performed an intention-to-treat analysis (ITT), which has
been proven to be the least biased technique to estimate intervention effects in RCTs [68]. This is
because an ITT tests the hypothesis of a null effect of treatment in a statistically valid way, and if
participants do not fully adhere to their assigned treatment an ITT underestimates the treatment
effect [69]. To maintain the benefits of randomization, ITT requires the comparison to be based
upon the treatment and control groups participants were randomly assigned to. In contrast, per-
protocol analysis describes the outcomes of the participants who adhered to the research protocol,
which can be useful to estimate the intervention’s efficacy for those who actually received it. Never-
theless, this estimate is likely to be flawed (overestimated) due to nonadherence of participants
[68]. Likewise, this also means that the treatment effect might be overestimated in 11 RCTs.
Methodological differences between the RCT study design and our analysis of data from
standard care physiotherapy must also be discussed. Overall, the main difference between our
comparison of RCTs and observational standard care data is the fact that in the RCTs, super-
vised exercise therapy is randomly allocated to the patients, whereas in standard care patients
are naturally exposed to supervised exercise therapy. In the latter, voluntarily going to the
physiotherapist for supervised exercise therapy might be a characteristic of some patients and
these patients might be different from those who do not voluntarily seek help by their physio-
therapist for the treatment of intermittent claudication. It might be that patients with intermit-
tent claudication who chose physiotherapy are healthier than patients with intermittent
claudication that chose not to go to the physiotherapist. It might also be the case that the
patients who receive supervised exercise therapy in the context of standard care have been cho-
sen by someone else, such as the vascular surgeon who referred them to the physiotherapist for
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supervised exercise therapy. This possibly existing imbalance, which could also be called selec-
tion bias or referral bias, might have led to an overestimation of maximum walking distance
improvement after supervised exercise therapy [70]. Furthermore, treatment compliance may
not be equivalent between the RCT and the standard care setting. The correctness of data entry
in the EMRmight differ from the correctness of data entry from the RCT, because standard care
data is recorded within the workflow of daily practice and RCTs are often based on double-data
entry and data checks. Although there are of course discrepancies between both settings that are
the result of biological and methodological differences, a systematic review published in the New
England Journal of Medicine concluded that observational studies did not systematically overes-
timate the magnitude outcomes as compared with results of RCTs [70].
Conclusion
All RCTs included in the present study excluded moderate- to large segments of the population
of patients with IC and exclusion criteria applied were justified in only one-third of the trials.
Most of the exclusion criteria are also implicitly used in standard physiotherapy care and
because of this baseline characteristics of patients included in RCTs and patients treated in
standard physiotherapy care were comparable. However, a statistically significant and (border-
line) clinically relevant difference in the improvement in MWD after three and six months was
found. The difference between trial treatment response and standard physiotherapy care treat-
ment response suggests an underestimation of the benefits of SET for the standard physiother-
apy care setting. Moreover, the results of the present study might stimulate researchers and
health policy advisors to reconsider which study design serves best to communicate the effec-
tiveness of an intervention to stakeholders.
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